Irish clinical diagnostics company Trinity Biotech has acquired the blood bank screening and certain molecular assets of UK-based personalized medicine and clinical diagnostics firm Lab21, the companies said today.

The total cost of the acquisition was approximately $7.5 million, the companies said. The acquired business generates annual revenues of approximately $4 million, of which $3.5 million is generated from hemaggluttination- and antibody-based tests for syphilis, and the remainder from an immunoassay-based malaria screening product.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.